0
Article |

A REVIEW OF THE LITERATURE AND A DISCUSSION OF SILVER ARSPHENAMIN

H. E. MICHELSON, M.D.; DAVID M. SIPERSTEIN, M.A.
Arch Derm Syphilol. 1921;4(2):193-206. doi:10.1001/archderm.1921.02350210056007.
Text Size: A A A
Published online

Silver arsphenamin, the latest of the arsphenamin series of drugs, is now on the market, and is being used in America. There is no English literature to guide one in determining its qualities. Our communication is an effort to review the literature on silver arsphenamin and to draw conclusions therefrom.

Silver arsphenamin was suggested by Ehrlich, whose untimely death cut short his researches, which were continued by Kolle who finally elaborated silver arsphenamin. This drug was first used clinically in March, 1918.

Kolle,1 in 1918, in the first of a series of articles, gives the following table which shows that silver arsphenamin had a more profound effect on experimental syphilis than any of the other members of the arsphenamin group. He concludes from his work that silver when combined with the arsphenamin molecule forms a combination which has a greater spirocheticidal action than other combinations with which he worked.

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Correspondence

CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs